Listen Score
LS 28
Global Rank
TOP 10%

このポッドキャストについて 🔗

ホスト:
更新頻度:
biweekly
平均音声長:
45 minutes
ゲストインタビュー
スポンサーがいる
英語
アメリカ合衆国
80 エピソード
2023年9月25日から
episodic

最新エピソード 🔗

AI can design a molecule in seconds, however someone still has to build it and test it before it means anything. You're pouring resources into AI-driven molecule design, but nobody on your team has answered the harder question: can you actually make what the model just designed? Patrick Finn is…

過去のエピソードを検索

Data in Biotechの以前のエピソードを検索します。

以前のエピソード

Flow cytometry can find a cell population in seconds, but naming it consistently across labs is a problem still unsolved. If you've ever tried to compare cytometry data across studies, CROs, or even two scientists in the same lab, you know the frustration: everyone gates their own way, and the sa…
Ask a general AI model how many approved drugs hit a target, and it might tell you three when the real answer is six, sounding just as confident either way. If your team is grounding drug discovery decisions in AI output with no way to trace where the answer came from, you're one regulator's ques…
Most drug discovery genomic data comes from a thin slice of the world, and that bias follows every decision downstream. Your team can run a Mendelian randomization study on 35,000 patients and still walk away with a single signal that doesn't even apply to the population you care about. If your p…
Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly le…
Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it. If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap. John A…
In this episode of Data in Biotech, host Ross Katz sits down with Woody Sherman, Founder and Chief Innovation Officer at PsiThera, for a conversation on why AI can transform drug discovery's paperwork and code while barely touching the hardest part of the problem: the molecules themselves. Woody's …
In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul bring…
In this episode of Data in Biotech, host Ross Katz sits down with Arvind Rao, Professor of Computational Medicine and Bioinformatics at the University of Michigan, for a discussion on the gap between what biomedical AI can do and what it can reliably be trusted to do in clinical practice. Arvind's …
In this episode of Data in Biotech, host Ross Katz sits down with Sadegh Salehi, Director of Research and Principal Scientist at Overjet, to explore what rigorous model evaluation actually looks like when the stakes are clinical.  Overjet builds FDA-cleared vision models that detect and quantify …
免責: このページに埋め込まれているポッドキャストとアートワークは CorrDyn からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。